Edition:
United Kingdom

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

8.89EUR
20 Apr 2018
Change (% chg)

€-0.05 (-0.62%)
Prev Close
€8.94
Open
€8.97
Day's High
€8.97
Day's Low
€8.81
Volume
89,040
Avg. Vol
126,074
52-wk High
€13.68
52-wk Low
€7.65

Select another date:

Wed, Mar 14 2018

BRIEF-Nicox Announces Increase In Royalties From Bausch + Lomb For Vyzulta

* REG-NICOX ANNOUNCES IMPROVED FINANCIAL TERMS FROM BAUSCH + LOMB FOR VYZULTA

BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results

* ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON

BRIEF-Nicox Updates on Drug Development And Outlines 2018 Activities

* RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT

BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta

* Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

Select another date: